Zensights LLC

Introducing Zensights Federated Healthcare Advisory Panel: Vice Admiral Rocky Bono Vice Admiral Rocky Bono served with distinction for nearly 30 years as a Naval Officer, becoming the first woman surgeon in the military to attain the rank of Vice Admiral. As the former CEO and Director of the Defense Health Agency (DHA), she led a $50 billion global healthcare enterprise, integrating the healthcare services of all branches of the U.S. military—Army, Navy, and Air Force. Under her leadership, the DoD deployed its electronic health record system, one of the largest and most complex health IT implementations in the world, and advanced the largest federated health system in collaboration with the U.S. Department of Veterans Affairs. VADM Bono brings her extensive medical and leadership experience to life science companies. On March 22, 2020, she was appointed by Washington State Governor Jay Inslee to lead the state’s health system response to the COVID-19 pandemic, where she played a crucial role in coordinating efforts to manage the public health crisis. Her expertise lies in identifying the similarities and differences between commercial, private, and VA healthcare environments, enabling companies to effectively operate and position themselves within these markets. She is particularly skilled in guiding companies through the DoD and VA formulary processes, ensuring that their products are not only effective and beneficial but also favorably positioned to serve the needs of military personnel. Additionally, VADM Bono’s deep understanding of patient advocacy within the military and veteran communities allows her to identify key opportunities for life science companies to engage with patient cohorts and advocacy groups. Her strategic insights into the healthcare needs of service members and veterans help companies align their products with the priorities of the DoD and VA, ultimately ensuring that the right medications reach those who need them most. VADM Bono offers companies a unique lens into the DoD and VA, simplifying the complexities of these systems and facilitating effective engagement. Her unparalleled experience within the military healthcare system makes her an invaluable resource for any life science company looking to succeed in the federated healthcare space. #ZensightsFHAP #FederatedHealthcare #AdvisoryPanel #DHA

Introducing Zensights Federated Healthcare Advisory Panel: Dr. Shulkin Dr. David J. Shulkin, the Ninth Secretary of the U.S. Department of Veterans Affairs (VA), brings an unparalleled depth of experience in healthcare management and veteran care. Appointed to lead the VA by President Trump and unanimously confirmed by the U.S. Senate (making him the only cabinet nominee by President Trump to have unanimous approval), Secretary Shulkin led the nation’s largest integrated healthcare system, overseeing over 1,200 sites of care and serving more than 9 million veterans. Before this, he was appointed by President Obama as Under Secretary of Health for the VA, where he was also unanimously confirmed by the Senate, reflecting the bipartisan trust in his leadership and expertise. Before his tenure at the VA, Secretary Shulkin was a widely respected healthcare executive, holding key positions as chief executive of renowned hospitals and health systems, including Beth Israel Medical Center in New York City and Morristown Medical Center in New Jersey. His deep commitment to patient-centered care and outcomes-driven management earned him a reputation as one of the most influential figures in American healthcare. His work has always been grounded in a fundamental belief in putting patients first—a principle that guided his tenure at the VA and continues to influence his work today. During his time as Secretary, Dr. Shulkin implemented significant reforms to enhance transparency and access to care, such as publicly posting quality data and wait times for all VA facilities. He expanded access to mental health care for veterans with less than honorable discharges and took decisive actions to address critical issues, such as making suicide prevention the single highest clinical priority for the VA. His leadership was characterized by a relentless focus on addressing the urgent needs of veterans and improving the overall quality of their care. Now, Secretary Shulkin leverages his extensive experience to assist life science clients in navigating the complex VA system, ensuring that veterans receive timely and effective healthcare products. His expertise lies in understanding the unique challenges of getting care to veterans, from navigating regulatory pathways to forging strategic partnerships within the VA. Driven by a mission to ensure that those who have served our country have seamless access to the healthcare they need, Secretary Shulkin welcomes opportunities to continue supporting initiatives that improve care for veterans and their families. #ZensightsFHAP #FederatedHealthcare #AdvisoryPanel #VeteransAffairs

Navigating the Federated Healthcare Landscape In the world of life sciences, understanding the federated healthcare landscape is one of the most significant challenges facing the industry. Without a comprehensive understanding, companies risk misalignment with regulatory requirements, missed opportunities for critical partnerships, and the potential for their innovations to fail in reaching the service members and veterans who need them most. The Zensights Federated Healthcare Advisory Panel (FHAP) offers unmatched expertise to help life science companies navigate the complexities of the VA and DoD systems. Why is this so important? - Formulary Placement: Mastering the intricacies of VA and DoD formularies can determine whether your innovations reach the patients who need them. - Strategic Guidance: FHAP's leaders provide deep, informed insights into how and where to engage effectively within federal healthcare systems. Their expertise helps organizations chart the best course for integrating their products into care systems that serve millions. ... And so much more. Your innovations deserve the right strategy to make a meaningful impact. #StrategicGuidance #HealthcareInnovation #FederalHealthcare #Pharma #Biotech #FHAP

We are proud to announce the launch of the Zensights Federated Healthcare Advisory Panel (FHAP) The FHAP is a highly distinguished assembly of leaders from the U.S. Military and Government, designed to guide life science companies in navigating the complexities of the Department of Veterans Affairs (VA), the Department of Defense (DoD), and the broader federated healthcare system. With the panel’s deep knowledge, we are here to forge impactful partnerships that ensure seamless access to critical healthcare products for service members, veterans, and their families. The panel provides organizations with direct access to the most seasoned and respected leaders within the federated healthcare system, ensuring that they benefit from the highest caliber of guidance available. Stay tuned as we delve deeper into how the FHAP can serve as a transformative resource for your organization. #Veterans #MilitaryHealthcare #Leadership #Biotech #Pharma #HealthcareInnovation #FHAP

Welcoming Julia Brodsky Ph.D. to the Zensights Team! We are excited to announce that Julia is joining Zensights full-time as our Chief Client Experience Officer! Julia has been a valued Subject Matter Expert for Zensights, known for her exceptional leadership in Data Enablement, Data Science, and Analytics. Many of us at Zensights have had the privilege of working closely with Julia over the years, and we are delighted that she will now be dedicating her talents to enhancing our client experience. In this new role, she will be deeply involved in all aspects of our client projects, ensuring engagement is high, projects are delivered to the highest standards, and that our customers receive an exceptional experience. Julia’s journey in the pharmaceutical industry is marked by a relentless pursuit of excellence. With a Master’s Degree and PhD in Statistics from NYU Stern Business School, she has held key management positions in Data Science, Sales & Marketing Insights & Analytics, Managed Markets Insights & Analytics, Data Strategy, Data Enablement and Master Data Management. Her most recent role as VP, Head of Strategic Data Products for Novartis US Oncology, saw her architect and build a team from the ground up, delivering innovative Data and Analytics products that supported US Oncology. Julia’s passion for leveraging data and AI to drive patient-centric solutions is unmatched, and her ability to translate complex data into actionable insights has made her a standout leader in the industry. We are confident that Julia’s strategic vision and hands-on leadership will be instrumental in helping us solve complex challenges and deliver innovative solutions to our clients. We are thrilled to have Julia on board and look forward to the incredible impact she will have in her new role. Please join us in welcoming Julia to this exciting next chapter at Zensights!

Market Access and Reimbursement in Pharma Navigating the market access and reimbursement landscape can be complex, with each therapeutic area presenting its own unique challenges. Here are some key factors we consider: ✓ Evolving Payer Requirements: Payers are increasingly demanding real-world evidence and health economics and outcomes research data to support the value of new therapies. Building a robust evidence package early in development is crucial to meet these evolving standards. ✓ Patient-Centric Value Models: Traditional cost-effectiveness models are being supplemented by value frameworks that incorporate patient outcomes and quality of life metrics. Understanding and integrating these models into your market access strategy can improve alignment with payer expectations. ✓ Policy Changes Impacting Access: Recent changes in policy, notably the Inflation Reduction Act in the U.S., are reshaping how drugs are priced and reimbursed. Staying ahead of these changes and fully understanding their impacts before implementation is essential for maintaining market access. ✓ Innovative Contracting: Risk-sharing agreements and value-based contracts are becoming more common, allowing payers and manufacturers to share the financial risk associated with new therapies. Exploring these options can create win-win scenarios for both parties. #MarketAccess #Reimbursement #PharmaInsights #HealthcarePolicy #PatientValue

We are pleased to spotlight Laura Mezey, a valued Subject Matter Expert with Zensights: Laura’s extensive background in legal and compliance, M&A strategy, integration planning, and divestiture management spans over two decades, primarily at Bayer HealthCare. In her tenure at Bayer, Laura held significant leadership roles, including Vice President of Integration, Separation, and Transitions, and Global Division Counsel. Throughout her tenure at Bayer, Laura was instrumental in shaping and executing strategic initiatives across two global healthcare divisions, encompassing pharma, medical devices, diagnostics, and software. Her deep expertise in M&A strategy, integration planning, and divestiture management has been key in driving successful business transformations and cultural changes. Laura's career has been marked by her innovative approach to legal and compliance challenges, as well as her ability to navigate complex, cross-functional issues in a highly regulated industry. As the first lawyer dedicated to Bayer's Diabetes Care business, she played a crucial role in its evolution, from supporting the division’s growth to managing its divestiture. Laura’s work extended beyond legal counsel; she was a vital member of the global management team, contributing to strategic decisions that impacted the company's direction on a global scale. Laura led a team responsible for executing integration and separation strategies for Bayer’s significant transactions. She was the architect behind the company’s divestiture playbook, a comprehensive guide that has informed and improved subsequent transactions. Her pragmatic problem-solving skills, coupled with a forward-thinking mindset, have made her a trusted advisor in both high-growth and commoditizing business environments.   Laura's impact extends beyond her time at Bayer. She currently serves on the Board of Directors for Otsuka America Pharmaceuticals and as an Entrepreneur in Residence at DigitalDx Ventures, where she continues to contribute her strategic insights to the life sciences sector. We are lucky to have Laura on board and grateful for the valuable expertise she brings to our clients – if your organization is going through separations or integrations, there is no better individual than Laura to provide learned strategic guidance. #ZensightsSME #MAStrategy #IntegrationPlanning #SubjectMatterExpert

Private Equity Continues to Invest in Pharma Patient Services/HUB Companies. Notably this year, PharmaCord, AssistRX, and CoPilot have had Private Equity take partial or complete ownership in their organizations. These transactions are potentially impactful when/if key leadership rotates out of the organization. It is important to understand the strategic long term vision of these PE acquisitions — You should always be aware of ownership changes within the vendors you consider key strategic partners. Zensights can assist you in navigating and understanding the potential implications of these and other variables associated with Patient Services and HUB vendors. #PrivateEquityInPharma #PatientServices #HUB #Zensights

The name "Betsy Bondurant" is synonymous with "Gold Standard" when it comes to Strategic Meetings Management; there is no one else you'd rather have on your team. Given that, we're thrilled to announce that she's joined ours — Betsy is joining Zensights as a Subject Matter Expert. Betsy brings a unique 360° perspective with over 30 years of industry expertise in meeting & trade show management and procurement, including 20 years dedicated to Strategic Meetings Management (SMM). Her journey began in hotel sales and management, and in 1992 she moved to Amgen to run their Meetings and Trade Shows. During her 15-year tenure at Amgen, she developed and implemented a pioneering corporate-wide SMM program, showcasing her ability to lead and innovate within the industry.    In 2007, Betsy transitioned into consulting, leveraging her vast experience to provide unbiased appraisals and recommendations for SMM programs. Her expertise is widely recognized, making her a sought-after consultant, speaker and author. She has shared her insights on strategic meeting management, stakeholder management, and alignment with audiences across North America, Central America, Europe, and Asia. Betsy's dedication to policy work, data analysis, and benchmarking will be invaluable as she guides organizations in achieving consistent, high-quality outcomes for their events.    Betsy has been a driving force in the industry, holding significant roles in various associations. She served on the Global Business Travel Association (GBTA) Meetings committee, most recently as Vice-Chair, and was the 2023 Chair for the Events Industry Council (EIC) APEX Commission. Her long-standing involvement with Meeting Professionals International (MPI), including a three-year tenure on their International Board of Directors, underscores her commitment to advancing the industry. As a Certified Travel Executive (CTE) and Certified Meeting Manager (CMM), her credentials further demonstrate her authority in the field. Throughout her career, Betsy has received numerous accolades, including the GBTA “Presidents Award” in 2021, Business Travel News Best Practitioner of the Year Award, Meeting News “25 Most Influential People in the Meetings Industry,” and MPI Chairwoman's award.   With all that said, it’s easy to understand why we are honored to have Betsy join the Zensights team. Betsy will continue to apply her strategic expertise, particularly in procurement and meetings management, helping clients optimize their supplier base, manage RFP processes, and drive cost efficiencies. Please join us in welcoming Betsy! #ZensightsSME #StrategicMeetingsManagement #MeetingsAndEvents

We are excited to welcome Karen Lynch to our team as a Subject Matter Expert joining Zensights. With over 20 years of corporate and consulting experience, Karen is a highly skilled executive coach, facilitator, and management consultant. Her extensive training across and expertise in emotional intelligence, leadership development, and change management makes her an invaluable addition to our team, particularly as it pertains to her experience guiding companies through assessments and change across the healthcare and pharmaceutical sectors.   Karen’s career began with American Express, where she developed deep expertise from various roles in meetings, events and tradeshows. Her leadership in operations, account management and global business development garnered her a 360 view into M&E. Over her 17 years there, Karen gained a comprehensive understanding across all industries, including manufacturing, technology, professional services, financial, retail, and healthcare. This diverse background laid the foundation for her transition into consulting, where she has implemented global programs and events for many companies, focusing on strategic processes and policy support for change management initiatives.   Now leading both a leadership development and a change management company, Karen has dedicated herself to her pivotal role. With over 2000 hours of coaching expertise, she is a Professional Certified Coach (PCC), as well as a Change Management Practitioner, working with senior executives, leaders, and teams to enhance leadership skills and both personal and organizational effectiveness. Within pharma, she particularly enjoys the process of identifying and implementing opportunities for change. On behalf of pharma clients, she has run several Global Assessments, interviewing stakeholders to gauge satisfaction and policy adherence. Research, benchmarking, payment process, organizational structure, technology roadmap, resource modeling, and pitch development are some of her key areas of expertise. Her work underscores the growing integration of marketing and event management, recognizing the interdependence where marketing drives revenue and meetings drive process, ensuring cohesive execution across the board.   Karen's ability to integrate strategic planning with personal development will be instrumental in helping pharmaceutical companies navigate the complexities of organizational change and leadership development. We are thrilled to have Karen on board and welcome her into our community. #ZensightsSME #MeetingsAndEvents #LeadershipDevelopment